Program
vorolanib
Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.
Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.
Drug pageVorolanib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticalsits history only | 141 open or running | phase 3since Mar 23, 2017 | May 22, 2013 | Jun 2027phase 1 · NCT07809802 |
| EyePoint Pharmaceuticalsits history only | 84 open or running | phase 3since Oct 30, 2024 | Feb 6, 2021 | Oct 2027phase 3 · NCT07449923 |
| Tyrogenexits history only | 20 open or running | phase 2since Jan 21, 2015 | Feb 14, 2011 | none ahead |
Also a collaborator on its studies: SynteractHCR.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 8 earlier studies, Feb 14, 2011 to Jul 19, 2018.
- Jun 9, 2016Named vorolanibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, EYP-1901, CM082
- Oct 15, 2018Phase 2 study in Macular DegenerationBetta Pharmaceuticals · NCT03710863 · 64 enrolled · China
- Dec 26, 2018Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT03792958 · 19 enrolled · China
- Feb 19, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT03848611 · 20 enrolled · China
- Apr 4, 2019Phase 2 study in Small Cell Lung CarcinomaBetta Pharmaceuticals · NCT03904719 · 30 enrolled · China
- Jan 7, 2020Phase 1 study in Myopic Choroidal NeovascularisationBetta Pharmaceuticals · NCT04222842 · 96 enrolled · China
- Mar 26, 2020Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT04328506 · 96 enrolled · China
- Jun 12, 2020Phase 1 study in Advanced Solid TumorBetta Pharmaceuticals · NCT04434326 · 4 enrolled · China
- Feb 6, 2021EyePoint Pharmaceuticals’ first study: phase 1 study in Wet Age-related Macular DegenerationNew to EyePoint PharmaceuticalsEyePoint Pharmaceuticals · NCT04747197 · 17 enrolled · United States
- May 9, 20222 phase 2 studiesEyePoint Pharmaceuticals · NCT05381948, NCT05383209
- Oct 19, 2023Phase 2 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT06099184 · 27 enrolled · United States
- Oct 30, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06668064 · 400 enrolled · United States
- Nov 8, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06683742 · 400 enrolled · United States, Brazil, Czechia and more
- Feb 27, 20262 phase 3 studies in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936, NCT07449923
- Sep 3, 2026Phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802 · 36 planned · China
Ahead
- Jun 2027Primary completion: phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802
- Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936
- Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449923
TargetBeta
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07809802Hepatic Impairment (HI) · China | 1 | Recruiting | Betta Pharmaceuticals | Jun 2027 | 36 |
| NCT07449936Diabetic Macular Edema · United States, Germany, Israel and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Oct 2027 | 240 |
| NCT07449923Diabetic Macular Edema · United States, Brazil, Czechia and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Oct 2027 | 240 |
| NCT06683742Wet Age Related Macular Degeneration · United States, Brazil, Czechia and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Sep 9, 2026 | 400 |
| NCT06668064Wet Age Related Macular Degeneration · United States | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Jul 13, 2026 | 400 |
| NCT06099184Diabetic Macular Edema · United States | 2 | Completed | EyePoint Pharmaceuticals | Oct 24, 2024 | 27 |
| NCT05383209Nonproliferative Diabetic Retinopathy · United States | 2 | Completed | EyePoint Pharmaceuticals | Feb 12, 2024 | 77 |
| NCT05381948Wet Age-related Macular Degeneration · United States | 2 | Completed | EyePoint Pharmaceuticals | Nov 29, 2023 | 161 |
| NCT04747197Wet Age-related Macular Degeneration · United States | 1 | Completed | EyePoint Pharmaceuticals | May 11, 2022 | 17 |
| NCT04434326Advanced Solid Tumor · China | 1 | Completed | Betta Pharmaceuticals | Oct 22, 2021 | 4 |
| NCT04328506Advanced Malignant Solid Tumors · China | 1 | Completed | Betta Pharmaceuticals | Jul 27, 2020 | 96 |
| NCT04222842Myopic Choroidal Neovascularisation · China | 1 | Suspended | Betta Pharmaceuticals | Dec 30, 2021 | 96 |
| NCT03904719Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jun 30, 2021 | 30 |
| NCT03848611Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Betta Pharmaceuticals | Feb 2021 | 20 |
| NCT03792958Advanced Malignant Solid Tumors · China | 1 | UNKNOWN | Betta Pharmaceuticals | Jun 2023 | 19 |
| NCT03710863Macular Degeneration · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jan 1, 2022 | 64 |
| NCT03602547Mucosal Melanoma · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jul 2019 | 40 |
| NCT03286244Advanced Gastric Cancer · China | 1 | UNKNOWN | Betta Pharmaceuticals | Aug 2019 | 21 |
| NCT03095040Renal Cell Cancer Metastatic · China | 3 | UNKNOWN | Betta Pharmaceuticals | Feb 2021 | 390 |
| NCT02577458Renal Cell Carcinoma Recurrent · China | 1 | UNKNOWN | Betta Pharmaceuticals | Mar 2018 | 18 |
| NCT02452385Macular Degeneration · China | 1 | Suspended | Betta Pharmaceuticals | Jun 2020 | 56 |
| NCT02348359Macular Degeneration · United States | 2 | Terminated | Tyrogenex | Dec 12, 2017 | 157 |
| NCT01863485Advanced Cancer · China | 1 | Completed | Betta Pharmaceuticals | Oct 2014 | 44 |
| NCT01296581Neoplasms · United States | 1 | Completed | Tyrogenex | Jan 2014 | 52 |
How it is read
Names in the registry
- “EYP-1901”, 8 entries
- “CM082”, 5 entries
- “CM082 plus JS001”, 3 entries
- “vorolanib”, 2 entries
- “X-82”, 2 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 7 studies
- Macular Edema, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Diabetic Retinopathy, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.